Evergreen Capital Management’s Cytokinetics CYTK Stock Holding History

Evergreen Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$580K	Buy	6,812 +2,792	+69%	+$200K	0.01%	824
2026 Q1	$265K	Buy	4,020 +619	+18%	+$39.3K	0.01%	1204
2025 Q4	$216K	Buy	+3,401	New	+$212K	﹤0.01%	1260
2024 Q2	–	Sell	-4,163	Closed	-$292K	–	965
2024 Q1	$292K	Buy	4,163 +758	+22%	+$58.6K	0.01%	642
2023 Q4	$284K	Buy	+3,405	New	+$123K	0.01%	614
2022 Q4	–	Sell	-4,217	Closed	-$204K	–	683
2022 Q3	$204K	Buy	+4,217	New	+$203K	0.01%	556

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evergreen Capital Management's CYTK Position: Q2 2026 in Review

Evergreen Capital Management increased its Cytokinetics (CYTK) stake by 69% in Q2 2026, buying an estimated $200K and bringing the position to 6,812 shares worth $580K. The position accounts for 0.01% of the portfolio, ranked #824.

Evergreen Capital Management first reported a position in CYTK in Q3 2022 and has held it in 6 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Evergreen Capital Management held 6,812 shares of Cytokinetics worth $580K as of Q2 2026.
Evergreen Capital Management bought 2,792 Cytokinetics shares in Q2 2026, an estimated $200K.
Cytokinetics made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #824 holding.
Evergreen Capital Management first reported a position in Cytokinetics in Q3 2022 and has held it in 6 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.